Tyler Van Buren
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
58
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $24.01 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $27.19 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $54.63 | +9.83% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $10.72 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $19.68 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $843.60 | +42.25% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $40.88 | - | 1 | Jun 24, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | n/a | $17.82 | - | 1 | May 15, 2024 | |
| GILD Gilead Sciences | Maintains: Buy | $90 → $85 | $89.51 | -5.04% | 5 | Apr 26, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $35 → $55 | $50.88 | +8.10% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $50.76 | -40.90% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.37 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.98 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $86.17 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.49 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.62 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $17.57 | +70.75% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.94 | - | 1 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.48 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.43 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $31.70 | +120.82% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.32 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $26.90 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.39 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.40 | +3,471.43% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $9.55 | +9,062.30% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $185 | $204.21 | -9.41% | 3 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $4.36 | +817.43% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $24.47 | +63.47% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $8.28 | +262.32% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.47 | +1,114.57% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $3.74 | +1,504.28% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $14.52 | +244.35% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.87 | +3,333.67% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $7.41 | +2,599.06% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.08 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.45 | - | 1 | Aug 4, 2017 |
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $24.01
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $27.19
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $54.63
Upside: +9.83%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $10.72
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $19.68
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $843.60
Upside: +42.25%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $40.88
Upside: -
NewAmsterdam Pharma Company
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $17.82
Upside: -
Gilead Sciences
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $89.51
Upside: -5.04%
Biohaven
Mar 1, 2024
Maintains: Outperform
Price Target: $35 → $55
Current: $50.88
Upside: +8.10%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $50.76
Upside: -40.90%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $20.37
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $33.98
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $86.17
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $54.49
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.62
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $17.57
Upside: +70.75%
Feb 14, 2023
Initiates: Outperform
Price Target: n/a
Current: $59.94
Upside: -
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $25.48
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.43
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $31.70
Upside: +120.82%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $3.32
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $26.90
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $16.39
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.40
Upside: +3,471.43%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $9.55
Upside: +9,062.30%
Nov 6, 2020
Downgrades: Underweight
Price Target: $185
Current: $204.21
Upside: -9.41%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $4.36
Upside: +817.43%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $24.47
Upside: +63.47%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $8.28
Upside: +262.32%
Aug 4, 2020
Initiates: Overweight
Price Target: $30
Current: $2.47
Upside: +1,114.57%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $3.74
Upside: +1,504.28%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $14.52
Upside: +244.35%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.87
Upside: +3,333.67%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $7.41
Upside: +2,599.06%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.08
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.45
Upside: -